...Perioperative chemotherapy, in particular platinum with or without etoposide, improves survival in the rare LCNEC.
Zobrazují se příspěvky se štítkemcisplatin. Zobrazit všechny příspěvky
Zobrazují se příspěvky se štítkemcisplatin. Zobrazit všechny příspěvky
13.03.11
Large Cell Neuroendocrine Carcinoma of the Cervix: Prognostic Factors and Survival Advantage With Platinum Chemotherapy - OncologySTAT
Large Cell Neuroendocrine Carcinoma of the Cervix: Prognostic Factors and Survival Advantage With Platinum Chemotherapy - OncologySTAT
06.02.11
Adding Bevacizumab to Chemo Raises Treatment-Related Mortality - OncologySTAT
Adding Bevacizumab to Chemo Raises Treatment-Related Mortality - OncologySTAT
...Treatment with taxanes and platinum agents appeared to raise the risk of fatal events associated with bevacizumab. This may reflect an interaction between these classes of drugs and bevacizumab...
06.11.10
Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO
Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO
.....
Do these data suggest that we should incorporate platinum agents into adjuvant or neoadjuvant therapy in BRCA1 carriers? No. On the basis of currently available evidence, we cannot say that there is definitive evidence of a platinum benefit in triple-negative or even BRCA1-associated breast cancer, nor can we say that there is adequate evidence to routinely incorporate platinum agents into adjuvant or neoadjuvant therapy for any identifiable subtype of breast cancer. What we can say is that this is a reasonable avenue to pursue in prospective trials, and we can feel reassured that the clinical evidence thus far fits with preclinical models. With the advent of rational approaches developed from BRCA1-associated models, which we hope will be successfully applied to sporadic basal-like breast cancer, we will finally alter the prognostic landscape for patients with this disease.
.....
Do these data suggest that we should incorporate platinum agents into adjuvant or neoadjuvant therapy in BRCA1 carriers? No. On the basis of currently available evidence, we cannot say that there is definitive evidence of a platinum benefit in triple-negative or even BRCA1-associated breast cancer, nor can we say that there is adequate evidence to routinely incorporate platinum agents into adjuvant or neoadjuvant therapy for any identifiable subtype of breast cancer. What we can say is that this is a reasonable avenue to pursue in prospective trials, and we can feel reassured that the clinical evidence thus far fits with preclinical models. With the advent of rational approaches developed from BRCA1-associated models, which we hope will be successfully applied to sporadic basal-like breast cancer, we will finally alter the prognostic landscape for patients with this disease.
14.04.10
Cisplatin
Nežádoucí účinky
Neurotoxicita
- jde o senzitivní neuropatii
- uplatňuje se především v oblasti vlastního neuronálního těla
- kumulativní dávka cisplatiny ke vzniku neurotoxicity je 300-600 mg/m2
- neurotoxicita vzniká i po intraperitoneální aplikaci
- klinika: parestézie, které se mohou šířit i do proximálních oblastí končetin
- nejvíce bývá postižena vibrace
- může vzniknout až několik měsíců po vysazení léku a progredovat několik týdnů až měsíců po vysazení léku (u 30% pacientů)
- prevence vzniku: vitamin E a-tokoferol 400 mg / den závěry nejsou jednoznačné
Novinky
PeerView
Články
Cancer Care Ontario pdf
Přihlásit se k odběru:
Příspěvky (Atom)